PediAid
PediAid
loading academics…

DETECT Trial – Early Targeted Treatment of Patent Ductus Arteriosus

DETECT · BMJ – DETECT Trial⁠ · 2014

The DETECT trial was a multicentre, double-blind, randomized placebo-controlled study evaluating early indomethacin (within 12 hours) in 92 preterm infants <29 weeks' gestation with a large PDA. Early treatment significantly reduced pulmonary hemorrhage and the need for subsequent PDA treatment but did not improve the primary outcome of death or abnormal cranial ultrasound. Premature termination due to indomethacin unavailability limited statistical power. The findings suggest potential pulmonary benefits but insufficient evidence to support routine early indomethacin therapy.

Early indomethacin significantly reduced early pulmonary hemorrhage (2% vs 21%).

There was no statistically significant improvement in the primary composite outcome of death or abnormal cranial ultrasound.

Early treatment reduced the subsequent need for open-label PDA treatment.

The trial was discontinued prematurely because indomethacin became unavailable.

Small sample size of only 92 randomized infants.

Premature termination reduced statistical power.

The study was not powered to assess long-term neurodevelopmental outcomes.

The trial did not directly compare early versus delayed indomethacin administration.

Limited generalizability to infants ≥29 weeks or those without a large PDA.

Early targeted indomethacin may reduce pulmonary hemorrhage in extremely preterm infants with a large PDA.

No significant benefit was demonstrated for the primary composite outcome.

Routine early indomethacin treatment cannot be recommended solely on the basis of this trial.

The optimal timing and selection of infants for PDA treatment remain uncertain.